Tuagon, Mark Jade P.
HRN: 19-96-54 Sex: MalePatient Encounter
Audit Details
Audit Date
Antimicrobial
Start Date
End Date
Route
Dose
Frequency
Indication Documented
01/16/2023
CEFUROXIME 1.5GM (VIAL)
01/16/2023
01/23/2023
IVTT
360mg
Q8
BFC; PCAP C
Waiting Final Action
Indication: Empiric Type of Infection: Pneumonia Compliance to guidelines: Compliant To Guidelines
Initial appropriateness: Yes
Final appropriateness: Yes
Overall appropriateness: Yes